-20.9%
VST vs MRNA
+511.3%
-532.2%
-38.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.5% | -2.2% | +5.8% | +3.6% |
| 7D | +8.9% | +5.5% | +3.4% | +8.8% |
| 30D | +6.2% | +158.7% | -152.5% | +3.7% |
| 3M | -2.7% | +182.1% | -184.9% | -5.7% |
| 6M | -8.4% | +151.8% | -160.2% | -11.4% |
| YTD | -7.2% | +393.6% | -400.8% | -8.7% |
| 1Y | -20.9% | +499.5% | -520.4% | -19.1% |
| All | -20.9% | +511.3% | -532.2% | -19.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling